Mike Severino

CEO of Tessera Therapeutics developing RNA-based gene-writing platforms inspired by mobile genetic elements to make durable, in vivo genome changes for diseases like alpha-1 antitrypsin deficiency and sickle cell disease.

Best podcasts with Mike Severino

Ranked by the Snipd community

Jan 22, 2026 • 49min

EP 223: Live at JPM: Rewriting disease with next-generation genetic medicines with Michelle Werner of Alltrna and Mike Severino of Tessera Therapeutics

Join Michelle Werner, CEO of Alltrna, who focuses on engineered tRNA therapeutics for rare genetic diseases, and Mike Severino, CEO of Tessera Therapeutics, specializing in RNA-based gene-writing platforms. They discuss how 2026 is a pivotal year for clinical trials, share groundbreaking preclinical results, and explore innovative strategies for addressing genetic mutations. The duo also highlights the importance of patient advocacy and the adaptability of their platforms to tackle various genetic disorders, marking a promising future in genetic medicine.

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app